ArticleCureus2025
Clinicopathological Correlation of Immunohistochemical Markers, Serum Biomarkers, and Masticatory Muscle Activity With the Severity of Oral Submucous Fibrosis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral submucous fibrosis (OSMF) is a chronic, progressive condition recognised for its potential to undergo malignant transformation. Molecular biomarkers and functional muscle alterations may help predict disease progression and risk of transformation to oral squamous cell carcinoma (OSCC).
objectiveTo evaluate immunohistochemical (IHC) expression of p63, Ki-67, SOX2, and E-cadherin; correlate their expression with clinical and histological grades of OSMF; assess serum iron and protein levels; and analyse masticatory muscle thickness and electromyographic activity.
methodsA cross-sectional study was conducted over 18 months, including 30 OSMF patients, five healthy controls, and five OSCC patients. Clinical grading (Mehrotra), histological grading (Khanna and Andrade), immunohistochemical expression of p63, Ki-67, SOX2, and E-cadherin markers, serum biochemical profiling, ultrasonographic measurement of muscle thickness, and needle electromyography were performed.
resultsE-cadherin expression showed a significant and gradual reduction from normal mucosa to OSMF and further to OSCC (p = 0.017), whereas p63, Ki-67, and SOX2 exhibited significant progressive increases across the same continuum (p < 0.001). However, none of these markers showed a statistically significant correlation with the clinical or histological grades of OSMF. Serum iron, ferritin, and total protein parameters did not exhibit significant associations with the clinical grade of OSMF. In contrast, ultrasonography revealed a significant decline in the thickness of the masseter, temporalis, and orbicularis oris muscles with advancing clinical grades of OSMF (p < 0.05), indicating progressive myofascial involvement. Electromyographic findings corroborated these observations, with a reduction in motor unit action potential duration in the masseter muscle across advanced grades, reflecting underlying myopathic changes associated with fibrosis.
conclusionp63, Ki-67, SOX2, and E-cadherin demonstrate significant expression across normal mucosa, OSMF, and OSCC, supporting their role as markers of malignant transformation. However, these biomarkers do not reliably reflect disease severity within OSMF. Ultrasonographic and electromyography (EMG) assessments correlate with clinical progression and may serve as valuable adjuncts for early detection of muscle dysfunction in OSMF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.